Shots:
- Basilea Pharmaceutica entered into an exclusive license deal with Venatorx Pharmaceuticals to acquire global rights to ceftibuten-ledaborbactam etzadroxil, a P-III oral beta-lactam/beta-lactamase inhibitor (BL/BLI) combination for complicated urinary tract infections (cUTI), incl. pyelonephritis
- Under the agreement, Venatorx will receive an upfront payment along with potential milestone payments in 2025 and will also be eligible for up to $325M in commercial milestone payments plus tiered mid-single-digit royalties following successful P-III completion, regulatory approval, and commercialization
- The deal is expected to add ~CHF 15M in 2025 R&D expenses, with updated full-year guidance to be issued on Aug 19, 2025
Ref: Basilea| Image: Basilea and Venatorx | Press Release
Related News:- Bayer Enters a ~$1.3B Deal with Kumquat Biosciences to Develop and Commercialize a KRAS G12D Inhibitor
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
